Timing note: the event date supplied is August 4, 2026. Since today is also August 4, this preview treats the report as imminent/today rather than “tomorrow.”
DOC enters 2Q26 with a meaningfully improved setup versus the start of the year. The core debate has shifted from whether Healthpeak can stabilize its lab portfolio to whether it can translate improving life-science demand, continued outpatient-medical strength, and senior-housing growth into a credible 2027 FFO growth narrative.
The company’s first-quarter results established three important points:
The stock has already recognized much of the improved narrative—closing at $21.65 on August 3, up roughly 34% year to date—so the bar is no longer simply a clean quarter. Investors will likely want confirmation that lab occupancy is progressing, senior housing is sustaining its outperformance, capital recycling is on schedule, and 2026 guidance has room to hold or move higher.
Lab remains the central issue for DOC. In 1Q26:
The 2Q report should clarify whether the improved pipeline is converting into executed leases and, more importantly, whether near-term commencements support the promised year-end occupancy increase.
What would be constructive - Sequential growth in lab occupancy. - Evidence that signed leases are commencing as expected. - Stable or improving lease economics, particularly tenant-improvement requirements and net effective rents. - Better visibility on 2027 expirations and potential tenant move-outs. - Continued momentum at Gateway Crossing in South San Francisco.
What would concern investors - Occupancy stagnation or a new material known vacancy. - Leasing that is concentrated in shorter-term or heavily concessionary deals. - Further deterioration in same-store lab NOI without a clearer recovery timeline. - A softer outlook for biotech funding, tenant decision-making, or demand outside South San Francisco.
The important distinction is that occupancy, not face rent, is the main earnings lever. DOC has substantial vacant lab space that currently produces little revenue while still carrying operating costs; incremental absorption therefore has meaningful embedded operating leverage.
Outpatient medical is DOC’s most dependable business and should provide stability while lab recovers. In 1Q26, the portfolio generated:
This segment accounts for the largest share of same-store NOI, making its continued execution especially important to protecting 2026 FFO.
For 2Q, investors should focus less on quarter-to-quarter leasing volume—which management characterizes as seasonal—and more on:
A continued mix of mid-single-digit releasing spreads and low capital intensity would reinforce the view that outpatient medical can compound NOI even in a slower macro environment.
Senior housing was the standout operating segment in 1Q26. Same-store adjusted NOI rose 13.8%, driven by higher occupancy and resident-fee growth. The Janus Living IPO adds complexity but is central to the investment case:
The key question is whether the attractive demographic and operating backdrop in senior housing can offset the temporary IPO-related drag, public-company costs, and dilution from the noncontrolling interest.
Key items to watch - Same-store occupancy and RevPOR growth. - Labor, utilities, and other cost inflation. - Progress on the roughly $400 million of Janus acquisitions previously under contract. - Timing of acquisition closings and the expected earnings contribution. - Any change to the expected 2026-neutral / 2027-accretive IPO framework.
A strong Janus update would support the argument that DOC has retained much of the economic upside of a fast-growing senior-housing platform while unlocking a better valuation and external-growth vehicle for that business.
After 1Q, DOC raised 2026 FFO-as-adjusted guidance to $1.71–$1.75 per share, from $1.70–$1.74 previously. First-quarter FFO as adjusted was $0.45 per share, but management emphasized that this was elevated by the timing of senior-housing acquisitions and that subsequent quarters should normalize closer to the full-year run rate.
At the $1.73 midpoint, the remaining three quarters imply an average of roughly $0.43 per share.
A result around that implied quarterly run rate could be adequate if accompanied by:
Conversely, a modest FFO beat without stronger lab or capital-allocation evidence may not be enough after the stock’s rally.
Management has positioned capital allocation as a differentiator. In 1Q and shortly thereafter, DOC:
The company also entered 2026 with meaningful liquidity, but it has refinancing exposure. Management highlighted that $650 million of 3.5%-ish senior notes needed refinancing in June, creating a second-half interest-expense headwind relative to the first half.
The 2Q call should help investors assess whether DOC can continue to recycle capital from lower-growth or noncore assets into either:
This is particularly relevant because DOC’s equity story rests partly on the gap between private-market asset values and the public-market valuation of the company.
At $21.65, DOC trades at about 8.0x the midpoint of 2026 FFO-as-adjusted guidance. The annualized common dividend is $1.22 per share, implying an approximate 5.6% dividend yield at that price.
That valuation is not demanding if investors accept three propositions:
However, the recent share-price appreciation means the market has already begun to price in a better operating outlook. The next leg higher likely requires operational confirmation rather than just an attractive headline FFO number.
The setup is constructive, but expectations are higher. DOC has transitioned from a “show me” story to an execution story: outpatient medical is working, senior housing is growing, Janus has created a new strategic lever, and lab demand appears to be improving.
For this report, the most important signal will be whether management can substantiate its claim that lab occupancy is on a durable upward path. If it can, investors may increasingly value DOC on 2027 earnings power rather than the currently depressed lab NOI base. If lab progress disappoints, the stock’s recent rerating leaves less room for patience.